Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Keros Therapeutics ( (KROS) ) has shared an announcement.
On February 18, 2026, Keros Therapeutics announced that President and CEO Jasbir S. Seehra will represent the company at three major healthcare investor conferences in late February and early March 2026. He is scheduled for a corporate presentation at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, followed by fireside chats at the TD Cowen Health Care Conference on March 3 and the Leerink Partners Global Healthcare Conference on March 10.
Keros will provide archived replays of each appearance for up to 90 days in the Investors section of its website, underscoring its ongoing efforts to increase visibility and engagement with the investment community. The planned conference participation highlights the company’s aim to communicate its clinical pipeline progress and strategic direction to current and potential stakeholders in the biopharmaceutical sector.
The most recent analyst rating on (KROS) stock is a Buy with a $23.00 price target. To see the full list of analyst forecasts on Keros Therapeutics stock, see the KROS Stock Forecast page.
Spark’s Take on KROS Stock
According to Spark, TipRanks’ AI Analyst, KROS is a Neutral.
The score is driven primarily by improving financial performance and a strong, low-leverage balance sheet, supported by reasonable valuation and positive corporate actions (capital return and strategy updates). These positives are tempered by weaker near-term technical momentum (negative MACD, RSI below 50, and price below the 20-day average).
To see Spark’s full report on KROS stock, click here.
More about Keros Therapeutics
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel protein therapeutics for disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins. Its lead candidates include rinvatercept (KER-065) for Duchenne muscular dystrophy and amyotrophic lateral sclerosis and elritercept for treating cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndrome and myelofibrosis.
Average Trading Volume: 605,173
Technical Sentiment Signal: Sell
Current Market Cap: $505.1M
Learn more about KROS stock on TipRanks’ Stock Analysis page.